42 results
The main objectives are to understand how clinical markers and biomarkers previously identified in younger and older AD cohorts apply to the extreme elderly (90+ years old) and to identify novel biomarkers linked with resilience to developing…
The primary objective is to determine if there is a difference in autonomic function between patients with Alzheimer*s disease (MCI and AD) and a matched control group. The secondary objectives will be explorative and aimed to investigate…
To investigate effect of a single dose of MK-1167 on glutamate levels in the brain using MRS. Glutamate is a chemical that sends signals between nerve cells in the brain. To test the safety and tolerability of single oral doses of the trial drug, MK…
The overall aim of the current study is to improve quality of life in patients with cognitive disorders. First, by improving diagnosis of PTSD symptoms in these patients. Second, we will estimate comorbidity rate of PTSD in clinical populations of…
The main objective of the study is to investigate MEG-based hippocampal and whole brain neuronal hyperactivity in preclinical DIAD mutation carriers and to find proof-of-concept for the translatability of findings from preclinical AD mouse models to…
To 1) clinically validate the novel PET-tracer [18F]AV1451 for tau pathology as a diagnostic and prognostic marker in tauopathies, 2) to examine the (change in) (regional) binding of [18F]AV1451 across tauopathies, and the relationships between (…
To investigate whether tear biomarkers can differentiate between patients and controls, and between patient groups.
Zie onderzoeksprotocol.
The current study aims to obtain a better understanding of glymphatic dysfunction in dementia of the Alzheimer*s type and its preclinical stages.The main objective of this study is to improve our understanding of the potential link between…
The overall aim is to investigate whether a coach-supported mHealth intervention for lifestyle improvement can reduce the risk of dementia in those with low SES and/or a migration background aged 50-75 years. The specific objectives are to…
The aim of this study is two-fold:1.To elucidate the role of neuroinflammation in FTLD2.To identify biomarkers to predict and monitor disease progression in FTLD3.To differentiate FTLD-TDP from FTLD-tau during life using biomarkers for…
What is the comparative efficacy and safety between dementia diagnostics in primary care and dementia diagnostics in a memory clinic for older persons with memory complaints?
In this study we will investigate how safe the new compound deramciclane is, when it is given alone and in combination with the existing medication dextromethorphan (Part B), and how well it is tolerated when it is used by healthy elderly…
Determination of possible Alzheimer pathology in the brain and to follow-up participants over time (by means of another research protocol). In addition, its [18F]-label with a half-life of 110 minutes will enable use in hospitals without an on-site…
The main objective of the study is to collect digital data for the tests that are currently hosted on the Cognitive Dx platform and to use this data to develop and refine the existing algorithms that automatically score the test. Secondary…
Discontinuation of ANtihypertensive Treatment in Older people with dementia living in a Nursing home
To assess whether discontinuation of antihypertensive treatment in nursing home residents with dementia a) reduces NPS and improves quality of life; b) improves general daily functioning and cognitive functioning; c) reduces psychotropic medication…
We aim to assess the association between (cardio-)vascular and hemodynamic factors in relation to cognitive function.
The primary objective of the MANTA-study is to investigate MEG-based network topology and 'activity dependent degeneration' as mechanisms in the stereotypical spread of tau pathology (18F-AV1451 retention) in preclinical and clinical…
The overall aim of this study is to develop a short and clinically relevant composite measure, which is able to detect changes in cognition and everyday functioning across the disease spectrum of Alzheimer*s Disease (AD). We will achieve this aim by…
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.